Abliva to Hold Virtual KOL Event on KL1333 for Primary Mitochondrial Disease on May 21, 2024
LUND, Sweden, May 13, 2024 – Abliva AB (Nasdaq Stockholm: ABLI), a company in the clinical stages of drug development targeting rare and severe primary mitochondrial diseases, announced it will host a virtual Key Opinion Leader (KOL) event on Tuesday, May 21, 2024, at 10:00 AM ET / 4:00 PM CET. The event will feature Amel Karaa, MD from Massachusetts General Hospital, who will shed light on the unmet medical needs and the existing treatment landscape for patients suffering from primary mitochondrial disease. At present, no medications have been approved for this systemic condition. Those interested can register for the event via a provided link.
The event will primarily center around Abliva's leading program, KL1333, which has demonstrated promising early signs of effectiveness in patients with mitochondrial disease. This innovative therapy works by targeting the fundamental pathophysiology of mitochondrial disease. KL1333 is currently under investigation in a potentially registrational Phase 2 FALCON trial, and interim analysis results are anticipated by mid-2024. The drug has received Orphan Drug Designation (ODD) in Europe and the U.S. and has also been granted Fast Track designation in the U.S.
About Dr. Amel Karaa
Dr. Amel Karaa is an internist and clinical geneticist specializing in primary mitochondrial diseases at Massachusetts General Hospital in Boston. She is actively involved in clinical research and has led several national and international clinical trials for mitochondrial diseases at various stages of drug development. Dr. Karaa was named the United Mitochondrial Disease Foundation (UMDF) fellow in 2013 and is a site investigator for the NIH North American Mitochondrial Disease Consortium (NAMDC). She is also one of the founders and directors of the Mitochondrial Care Network (MCN), which manages mitochondrial disease expert centers in the U.S. Furthermore, Dr. Karaa serves as the chair of the scientific/medical board of the UMDF and is the immediate past-president of the Mitochondrial Medicine Society (MMS). Recently, she has concentrated on establishing a U.S. wide clinical trial consortium for primary mitochondrial disorders, known as the Translational Research Advancing Therapy in Mitochondrial Diseases Consortium (TREAT MITO).
Abliva – Advancing Mitochondrial Health
Abliva is dedicated to discovering and developing treatments for mitochondrial diseases, which are rare and often severe conditions that result from malfunctioning mitochondria, the energy providers of cells. The company has prioritized two key projects: KL1333, a potent regulator of the essential co-enzymes NAD⁺ and NADH, which has progressed into late-stage development; and NV354, an energy replacement therapy that has completed preclinical development. Abliva is headquartered in Lund, Sweden, and is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
